Discrimination of breast cancer by anti-malignin antibody serum test in women undergoing biopsy

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 10, 2005, Pages 2310-2315

  Harman, S Mitchell ^a   Gucciardo, Frank ^a   Heward, Christopher B ^b   Granstrom, Per ^c   Barclay White, Belinda ^d   Rogers, Lowell W ^e   Ibarra Jr , Julio A ^f  

^a Kronos Longevity Research Institute   (United States)

^b Kronos Science Laboratories   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d Breastnet   (United States)

^e Memorial Care   (United States)

^f Orange Coast Memorial Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MALIGNIN ANTIBODY; PEPTIDE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTI MALIGNIN ANTIBODY SERUM TEST; ARTICLE; BENIGN TUMOR; BREAST BIOPSY; BREAST CANCER; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTI-IDIOTYPIC; BIOPSY, NEEDLE; BREAST NEOPLASMS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 26444486524     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0802     Document Type: Article

References (32)

1. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA 2000;283:2975-8.
2. De Koning HJ. Breast cancer screening; cost-effective in practice? Eur J Radiol 2000;33:32-7.
3. Hu YC, Sidransky D, Ahrendt SA. Molecular detection approaches for smoking associated tumors. Oncogene 2002;21:7289-97.
4. Ahrendt SA, Chow JT, Xu LH, et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999;91:332-9.
5. Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin Chim Acta 2002;315:157-68.
6. Cheever MA, Disis ML, Bernhard H, et al. Immunity to oncogenic proteins. Immunol Rev 1995;145:33-59.
7. Bogoch S. Astrocytin and rnalignin: two polypeptide fragments (recognins) related to brain tumor. J Natl Cancer Inst Monogr 1977;46:133-7.
8. Botti C, Martinetti A, Nerini-Molteni S, Ferrari L. Anti-malignin antibody evaluation: a possible challenge for cancer management. Int J Biol Markers 1997;12:141-7.
9. Bogoch S, Bogoch ES. Tumor markers: malignin and related recognins associated with malignancy rather than with cell type. Prog Clin Biol Res 1980;39:407-24.
10. Abrams MB, Bednarek KT, Bogoch S, et al. Early detection and monitoring of cancer with the anti-malignin antibody test. Cancer Detect Prev 1994;18:65-78.
11. Bogoch S, Bogoch ES, Iliescu VM. In vitro production of the general transformation antibody related to survival in human cancer patients: antimalignin antibody. Cancer Detect Prev 1988;12:313-20.
12. Bogoch S, Bogoch ES, Fager CA, et al. Determination of anti-malignin antibody and malignin in 1,026 cancer patients and controls: relation of antibody to survival. J Med 1982;13:49-69.
13. Thornthwaite JT. Anti-malignin antibody in serum and other tumor marker determinations in breast cancer. Cancer Lett 2000;148:39-48.
14. Smith TJ. All malignancy tests are not benign: the case for and against antimalignin antibodies. Clin Oncol Alert 1999;11:86-8.
15. Bogoch S, Bogoch ES. Quantitative determination of anti-malignin antibody. In: Frank RV, Rosenberg SA, editors. Perspectives in immunology: serologic analysis of human cancer antigens. New York: Academic Press; 1980. p. 693-6.
16. Bogoch S, Bogoch ES. A checklist for suitability of biomarkers as surrogate endpoints in chemoprevention of breast cancer. J Cell Biochem Suppl 1994;19:173-85.
17. Shah VI, Raju U, Chitale D, Deshpande V, Gregory N, Strand V. False-negative core needle biopsies of the breast. Cancer 2003;97:1824-31.
18. Ibrahim AE, Bateman AC, Theaker JM, et al. The role and histological classification of needle core biopsy in comparison with fine needle aspiration cytology in the preoperative assessment of impalpable breast lesions. J Clin Pathol 2001;54:121-5.
19. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. New York: Reinhold Co.; 1982.
20. Agresti A. A survey of exact inference for contingency tables. Stat Sci 1992;7:131-53.
21. Lai IR, Lee WJ, Huang MT, Lin HH. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterology 2002;49:1157-60.
22. Zheng H, He BF, Luo RC. Diagnostic value of combined detection of TPS, NSE and CEA in lung cancer. Di Yi Jun Yi Da Xue Xue Bao 2003;23:165-6.
23. Richardson TD, Oesterling JE. Age-specific reference ranges for serum prostate-specific antigen. Urol Clin North Am 1997;24:339-51.
24. Baltaci S, Aksoy H, Turkolmez K, et al. Use of percent free prostate-specific antigen density to improve the specificity for detecting prostate cancer in patients with normal rectal examinations and intermediate prostate-specific antigen levels. Urol Int 2003;70:36-41.
25. Lee AH, Denley HE, Pinder SE, et al. Excision biopsy findings of patients with breast needle core biopsies reported as suspicious of malignancy (B4) or lesion of uncertain malignant potential (B3). Histopathology 2003;42:331-6.
26. Harvey JM, Sterrett GF, Frost FA. Atypical ductal hyperplasia and atypia of uncertain significance in core biopsies from mammographically detected lesions: correlation with excision diagnosis. Pathology 2002;34:410-6.
27. Leifland K, Lundquist H, Lagerstedt U, Svane G. Comparison of preoperative simultaneous stereotactic fine needle aspiration biopsy and stereotactic core needle biopsy in ductal carcinoma in situ of the breast. Acta Radiol 2003;44:213-7.
28. Feuer EJ, Wun LM. DEVCAN: probability of developing or dying of cancer software, V, 4.1. vol 2003. National Cancer Institute; 1999.
29. Huffman KM, Gilliland FD, Adams-Cameron M, Hunt WC, Key CR. Prostate-specific antigen testing accuracy in community practice. BMC Fam Pract 2002;3:19.
30. Mattar R, Alves de Andrade CR, DiFavero GM, Gama-Rodrigues JJ, Laudanna AA. Preoperative serum levels of CA 72-4, CEA, CA 19-9, and α-fetoprotein in patients with gastric cancer. Rev Hosp Clin Fac Med Sao Paulo 2002;57:89-92.
31. Chester SJ, Maimonis P, Vanzuiden P, Finklestein M, Bookout J, Vezeridis MP. A new radioimmunoassay detecting early stages of colon cancer: a comparison with CEA, AFP, Ca 19-9. Dis Markers 1991;9:265-71.
32. Mercer DW, Talamo TS. Multiple markers of malignancy in sera of patients with colorectal carcinoma: preliminary clinical studies. Clin Chem 1985;31:1824-8.